APA (7th ed.) Citation

Muramatsu, A., Kobayashi, T., Kawaji-Kanayama, Y., Uchiyama, H., Sasaki, N., Uoshima, N., . . . Taniwaki, M. (2022). Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma. Leukemia & Lymphoma, 63(7), 1678. https://doi.org/10.1080/10428194.2022.2038373

Chicago Style (17th ed.) Citation

Muramatsu, Ayako, et al. "Pretreatment Serum Level of Interleukin-6 Predicts Carfilzomib-induced Hypertension in Relapsed/refractory Multiple Myeloma." Leukemia & Lymphoma 63, no. 7 (2022): 1678. https://doi.org/10.1080/10428194.2022.2038373.

MLA (9th ed.) Citation

Muramatsu, Ayako, et al. "Pretreatment Serum Level of Interleukin-6 Predicts Carfilzomib-induced Hypertension in Relapsed/refractory Multiple Myeloma." Leukemia & Lymphoma, vol. 63, no. 7, 2022, p. 1678, https://doi.org/10.1080/10428194.2022.2038373.